Non-melanoma skin cancer risk in the Queensland renal transplant population
Non-melanoma skin cancer risk in the Queensland renal transplant population
复制标题
DOI：
10.1046/j.1365-2133.2002.04976.x
复制
发表时间：
2002-11-01
影响因子：
10.3
通讯作者：
Harden, PN
中科院分区：
文献类型：
--
作者：
Ramsay, HM;Fryer, AA;Harden, PN
背景非黑色素瘤皮肤癌（NMSC）是实体器官移植的重要并发症，特别是在高紫外线暴露的地区。登记处的数据可能低估了规模的problem. ObjectivesA单观察员研究的昆士兰州肾移植人口之间进行了1999年7月和2000年4月利用横断面和回顾性数据。目的是准确地确定风险的NMSC肾移植后，并比较这与目前可用的注册data.Patients和方法的结构化面试和完整的皮肤检查完成了398肾移植受者。检查病例记录和组织学报告，以了解既往皮肤肿瘤的详细信息。从澳大利亚和新西兰的透析和移植登记处（ANZDATA）的341名受试者独立收集的数据也examined.Results一百八十七361（51.8%）移植受体的菲茨帕特里克皮肤类型I-IV开发了3979组织学诊断的NMSCs，因为第一次移植。SCC/BCC比值由移植前的1：3.7逆转为移植后的2：1。NMSC随着免疫抑制持续时间的增加而增加;分别有29.1%、52.2%、72.4%和82.1%的免疫抑制20年的患者至少发生了一种肿瘤。ANZDATA登记处记录的NMSC患者的人数为28.4%，并没有任何迹象表明肿瘤numbers.Conclusions NMSC是一个更大的临床问题，肾移植受者生活在亚热带昆士兰州，澳大利亚，比目前可用的登记数据。这对制定预防和监测战略具有影响。
Background Non-melanoma skin cancer (NMSC) is an important complication of solid organ transplantation, especially in areas of high ultraviolet light exposure. Registry data may underestimate the scale of the problem.Objectives A single-observer study of a Queensland renal transplant population was conducted between July 1999 and April 2000 utilizing both cross-sectional and retrospective data. The aims were to determine accurately the risk of NMSC following renal transplantation and compare this with currently available registry data.Patients and methods A structured interview and full skin examination was completed by 398 renal transplant recipients. Case notes and histology reports were examined for details of previous skin tumours. Independently collected data on 341 subjects from the Australia and New Zealand Dialysis and Transplantation Registry (ANZDATA) were also examined.Results One hundred and eighty-seven of 361 (51.8%) transplant recipients of Fitzpatrick skin types I-IV had developed 3979 histologically diagnosed NMSCs since first transplantation. The ratio of SCC/BCC was reversed from 1:3.7 before transplantation to 2:1 after transplantation. NMSC increased with duration of immunosuppression; 29.1%, 52.2%, 72.4% and 82.1% of those immunosuppressed for 20 years, respectively, had developed at least one tumour. The ANZDATA registry under-recorded the numbers of patients with NMSC by 28.4% and gave no indication of tumour numbers.Conclusions NMSC is a greater clinical problem in renal transplant recipients living in subtropical Queensland, Australia, than is shown by currently available registry data. This has implications for the development of prevention and surveillance strategies.